预约演示

Astellas and Osaka University to develop cell therapy

2024-07-22

细胞疗法基因疗法上市批准

Universal Cells’ UDC technology aids in the creation of cell therapy products from pluripotent stem cells. Credit: Andrei_R / Shutterstock.

Astellas Pharma subsidiaries the Astellas Institute for Regenerative Medicine and Universal Cells have signed a research partnership with the Graduate School of Medicine/Faculty of Medicine at Osaka University in Japan to develop pluripotent stem cell-derived cartilage organoid cell therapy.

The collaboration will focus on advancing the new treatment, aimed at addressing intervertebral disc degenerative disease.

Astellas Pharma has the rights to Universal Donor Cell (UDC) technology.Osaka University

This technology will aid in the creation of cell therapy products from pluripotenintervertebral disc degenerative disease

Universal Cellsmodifying the human leukocyte antigen (HLA) through gene editing, the UDC technology significantly reduces the risk of immune rejection.

See Also:Acorda loses Nasdaq listing to cap biotech’s end

Japan’s FY 2024 pricing reforhuman leukocyte antigen (HLA)ed innovative drugs

The threeAcordaies will merge the cartilage tissue creation protocol, Universal Cells’ UDC technology and AIRM’s extensive research and development (R&D) capabilities in cell therapy.

Astellas chief scientific officer Yoshitsugu Shitaka stated: “Astellas is committed to achieving our vision of being on the forefront of healthcare change, turning innovative science into value for patients.

“We hope to provide our cutting-edge UDC technology to academia and startups globally, and deliver next-generation cell therapies to patients. This partnership is an important step in the open innovation using UDC technology.”

Osaka University Graduate School of Medicine Department of Tissue Biochemistry and professor of molecular biology Noriyuki Tsumaki stated: “We believe that our cartilage-like tissue has the potential to regenerate intervertebral discs. We hope that combining our research with Astellas’ UDC technology and R&D cell therapy system will accelerate and realise the development of regenerative therapies to treat intervertebral disc degenerative disease.”

In March 2024, Astellas’ monoclonal antibody Vyloy (zolbetuximab) secured approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) in combination with chemotherapy for the treatment of gastric cancer.

Astellasene Therapy coverage on Pharmaceutical Technology is sAstellas by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipelineintervertebral disc degenerative disease

The cell and gene industry is gaining momentuVyloythzolbetuximabof therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collabgastric cancerore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as describCytivatheir Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Astellas